| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 93.8B | +5% |
| Gross Profit | 36.4B | - |
| Cost Of Revenue | 57.4B | +5% |
| Operating Income | 3.4B | -9% |
| Operating Expenses | - | - |
| Net Income | 2B | -10% |
| Amortization | 509MM | - |
| Interest Expense | 690MM | -0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Elevance Health offered skittish investors another signal that health insurers aren’t getting hit with higher-than-expected costs, reporting results that beat Wall Street expectations. Elevance stock rose over 5% early Thursday, on track for its highest close since December 2022. The earnings may help sustain a rally that began Tuesday, when UnitedHealth released results that also came in above analysts’ projections and said healthcare expenses were running at expected rates.
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The strength of a diversified enterprise, along with robust operational execution, is expected to be reflected in CVS Health's (CVS) first-quarter 2024 results.
CVS Health Corp (NYSE:CVS) recently announced a dividend of $0.67 per share, payable on 2024-05-01, with the ex-dividend date set for 2024-04-19. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into CVS Health Corp's dividend performance and assess its sustainability.
VictoryShares’ lineup of free cash flow ETFs has seen continued interest among investors. The VictoryShares Free Cash Flow ETF (VFLO) and the VictoryShares Small Cap Free Cash Flow ETF (SFLO) attracted strong interest and healthy flows in February 2024. VFLO saw over $31 million in net flows between February 1 and February 29, while the younger SFLO saw [...]
The U.S. government is investigating whether the consolidation of health insurers, pharmacy benefit managers and pharmacies is fueling high drug costs. The Department of Health and Human Services’ Office of Inspector General said it is examining whether health insurers' shared ownership of pharmacy-benefit managers and pharmacies has played a role in high drug prices. “We will determine the impact of related entity transactions within select vertically integrated entities on the prices for cov...
Health insurance stocks have been so battered this year that it doesn’t take much good news to move them higher. On Tuesday, UnitedHealth said its first-quarter adjusted earnings topped Wall Street’s estimates, despite a cyberattack on one of its units that weighed on the healthcare and insurance company’s results. Crucially for investors, UnitedHealth’s results implied that if one strips out some one-time costs associated with the cyberattack earlier this year, its core medical-loss ratio—a k...
Pharmacy benefit managers (PBMs) are in the crosshairs of Republicans and Democrats in Congress but have so far dodged any new litigation or reforms that had been targeted for inclusion in last month's U.S. government budget deal. Many lawmakers, drugmakers and government officials have pointed a finger at these industry middle men, suggesting they play a critical role in high prescription drug costs in the United States. The following is what you need to know about PBMs.
Friday, the Agency for Health Care Administration announced contracts to five health plans due for the re-procurement of the Statewide Medicaid Managed Care (SMMC) program. Florida has finally announced its long-awaited Medicaid contract awards, keeping Centene Inc (NYSE:CNC), Elevance Health Inc (NYSE:ELV), and Humana Inc (NYSE:HUM) as the only providers in each state region. Stephens noted that Centene and Elevance Health re-procured specialty contracts (MMASC) while Centene also retained its
Investors might get a better sense of the fallout for UnitedHealth Group when it reports first-quarter earnings results Tuesday.